Midpoint pricing, oversubscribed offering: Bambusa (BBTX.US) IPO raises $169 million, market cap locked at $815 million.

Zhitong Finance APP has learned that Bambusa Therapeutics Inc. (BBTX.US), an early-stage biotech company focused on dermatological and autoimmune diseases, raised $168.9 million through an upsized U.S. initial public offering (IPO), with the offering price set at the midpoint of the marketing range.